LabCorp’s New FSPx Offering Focuses on Clinical Analytics and Operations
The newly added service will focus on clinical analytics service and clinical operations capabilities.
LabCorp, a life sciences company headquartered in Burlington, NC, now has a laboratory solution added to its functional service provider (FSPx) offering as part of its Covance drug development business. The new service focuses on clinical analytics service and clinical operations capabilities. The company launched the new service in August 2019.
The clinical analytics portion of Laboratory FSPx will deliver global data solutions that enable clients to better manage laboratory data acquisition, data transfer, data transformation, data reconciliation, and site interactions, while the clinical operations sector will include clinical research associates, program managers, program leaders, regulatory staff, clinical trial leads, and clinical trial managers.
“Laboratory FSPx helps clients improve data readiness by integrating FSPx and central laboratory data teams from study setup to completion,” said Bill Hanlon, PhD, group president, Covance Clinical Development and Commercialization Services, in a company press release. “It also enables faster study start-up by implementing standards, lean processes, and blended roles.”
The new service will also help pharmaceutical and biotech companies to optimize costs, improve reconciliation, and streamline their operations.
“Whether it’s reducing the data reconciliation process time or reducing turnaround times for protocol amendments, Laboratory FSPx’s capabilities at Covance provide end-to-end solutions that help clients manage their laboratory operations,” said Paul Kirchgraber, MD, senior vice president, Clinical Trials Testing Solutions, Covance, in the press release. “The Covance FSPx portfolio of capabilities, now including Laboratory FSPx, meets the growing demands of the industry for flexible, best-in-class solutions for clinical research.”
Source: LabCorp
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
